Latest news with #HMB
Time of India
7 days ago
- Health
- Time of India
Can a dietary supplement provide the first effective treatment for liver cirrhosis?
Liver disease, a major global health concern, leads to millions of deaths annually due to complications like cirrhosis and liver cancer. Excitingly, a new study is exploring the potential of the dietary supplement HMB to treat cirrhosis, a condition affecting thousands in the UK. Liver disease accounts for two million deaths annually and is responsible for 4% of all deaths (1 out of every 25 deaths worldwide). The deaths are caused largely due to the complications of cirrhosis and liver cancer . What makes cirrhosis far more dangerous is that it is irreversible, and measures are taken to manage the condition, and in some a liver transplant is required. However, recent research has begun to explore whether certain dietary supplements can help, not just in managing cirrhosis but possibly even reversing or halting its progression. A new study led by scientists and clinicians from the University of Plymouth, the University of Southampton, and Imperial College London has looked into the possibility of treating cirrhosis with a dietary supplement. Before we delve into the details, let's try to understand what liver cirrhosis is. Cirrhosis is a condition in which the liver is scarred and permanently damaged. Scar tissue replaces healthy liver tissue and prevents the liver from working normally. This scar tissue also partly blocks the flow of blood through the liver. As cirrhosis gets worse, the liver begins to fail. Liver cirrhosis can increase the risk of developing liver cancer , specifically hepatocellular carcinoma (HCC). Can a dietary supplement cure liver cirrhosis A dietary supplement, Β-hydroxy β-methylbutyrate, otherwise known as HMB, used predominantly to build muscle bulk, prevent muscle loss as a result of ageing or illness, is to be trialled as a potential treatment for chronic liver disease. To understand this, the scientists and clinicians will test its potential in 60,000 people in the UK who have been diagnosed with cirrhosis. In the UK, this condition is most commonly caused by harmful alcohol use or fatty liver disease. In severe cases, some patients even require a liver transplant. As the condition worsens, it leads to over 75,000 hospital admissions and costs the NHS £17 billion annually. Through this study, the scientist will be looking at if taking HMB can offer a safe and effective way of improving patients' physical function and quality of life. Experts in liver disease, dietetics, and immunology from the University of Plymouth, University of Southampton, and Imperial College, London will be leading the trial. 'Cirrhosis is a condition that can have a significant impact on a person's physical and mental wellbeing. But while there are treatments in development, at the moment, there is nothing we can prescribe that directly addresses the condition. HMB has been identified as having the potential to fill that gap, with no suggestions at this time that there will be adverse side effects. This trial will hopefully enable us to test that fully, and establish whether HMB can indeed deliver real benefits for people with cirrhosis and those around them,' Dr Ashwin Dhanda, associate professor in Hepatology at the University of Plymouth and a Consultant in Hepatology at University Hospitals Plymouth NHS Trust, and the project's Chief Investigator, said in a statement. 7 Ways to check for fatty liver at home Patients have played a crucial role in shaping the study design. Lesley Manning, who previously underwent a liver transplant, is part of the project team and represents individuals with lived experience of advanced cirrhosis. 'Living with advanced cirrhosis is very debilitating. It makes you feel like you have no energy or strength, and there are no treatments out there to help manage your symptoms. I believe you need to look after yourself and the BOOST trial is testing something simple and safe that may improve the quality of life of people with advanced cirrhosis,' she said. One step to a healthier you—join Times Health+ Yoga and feel the change
Medscape
13-05-2025
- Health
- Medscape
Pain Relief With Linzagolix in UFs: PRIMROSE Trials
In women with uterine fibroids (UFs), pain relief with linzagolix was largely driven by a reduction in heavy menstrual bleeding (HMB), with a smaller contribution from a reduction in fibroid volume (FV). Hormonal add-back therapy (ABT) also affected these effects. METHODOLOGY: Researchers conducted a post hoc mediation analysis of pooled data from two double-blind placebo-controlled phase 3 trials (PRIMROSE 1 and 2) that included women aged 18 years or older with ultrasound-confirmed UFs and HMB. A total of 1012 participants (mean age, 42.3 years; 64% White; mean body mass index, 29.8; median total FV at baseline, 53 cm 3 ) were enrolled in the analysis; 75% of them reported moderate to severe pain and 43% reported severe pain at baseline. ) were enrolled in the analysis; 75% of them reported moderate to severe pain and 43% reported severe pain at baseline. Participants were randomly assigned to receive either linzagolix (100 mg and 200 mg, with and without hormonal ABT consisting of 1 mg oestradiol and 0.5 mg norethisterone acetate taken once a day) or placebo. The analysis focused on a clinically significant reduction in pain, defined as a change in two or more pain categories from baseline to week 24, assessed using the Numeric Rating Scale; HMB was assessed using the alkaline haematin method, and the FV was assessed using ultrasound. The primary outcome was the reduction in pain, mediated by reductions in HMB and FV. TAKEAWAY: The reduction in HMB explained between 28% and 51% of the effect of linzagolix on pain reduction across treatment arms, with odds ratios [ORs] ranging from 1.45 for 100 mg without ABT to 2.43 for 200 mg with ABT). The reduction in pain of 18.8%-30.9% vs 6.8% was achieved with linzagolix vs placebo. The reduction in FV accounted for 2%-8% of the treatment effect, with statistical significance noted only in the 200 mg without ABT arm (OR, 1.19; P = .002). = .002). The ORs for the total treatment effect on pain reduction ranged from 3.83 for 100 mg without ABT to 8.37 for 200 mg without ABT ( P < .001). < .001). The residual treatment effect, not explained by a reduction in HMB or FV, varied from 44% to 67% across treatment arms, reaching statistical significance only in the 200 mg without ABT arm ( P = .002). IN PRACTICE: "This analysis showed that reductions in pain were significantly mediated by reductions in HMB (all doses) and FV (200 mg alone) in linzagolix-treated women with UFs. Further research is needed to identify additional mediating factors," the authors of the study wrote. SOURCE: This study was led by Sven Becker, Department of Gynecology and Obstetrics, University Hospital Frankfurt, Frankfurt, Germany. It was published online on May 06, 2025, in BJOG: An International Journal of Obstetrics & Gynaecology . LIMITATIONS: This study could not explain all proportions of pain reduction, suggesting the need to explore other contributing factors. Pooling data from two trials might introduce bias, despite adjustments for factors like race and age. Pain was assessed globally as perceived by patients rather than by symptom type/location, which may have obscured the role of different pain types in the observed outcomes. DISCLOSURES: The PRIMROSE 1 and PRIMROSE 2 trials were funded by ObsEva. The current analysis was funded by Theramex. Several authors reported being employees and receiving honoraria from the funding agency and from various other sources.
Yahoo
24-04-2025
- Business
- Yahoo
Lexar Launches New Line of PCIe 4.0 and PCIe 5.0 SSDs Designed to Enhance Gameplay and Professional Applications
Built to accelerate performance and reduce lag and load times for gamers and creative professionals Key Features of Professional NM1090 PRO PCIe 5.0 SSD Provides speeds up to 14,000MB/s read, 13,000MB/s write1 A powerful 6nm controller optimizes heat control for efficient performance DRAM-based with SLC dynamic cache to improve performance and reduce latency Key Features of NQ780 PCIe Gen 4.0 SSD High performance meets exceptional value Delivers read/write speeds up to 7000/6000MB/s1 HMB and SLC cache technologies improve performance and user experience and reduce latency SAN JOSE, Calif., April 24, 2025 /PRNewswire/ -- Lexar, a leading global brand of flash memory solutions, is excited to announce the NQ780 M.2 2280 PCIe 4.0 NVMe SSD and the Professional NM1090 PRO PCIe 5.0 SSD, designed to provide the peak performance needed to keep every game running smoothly. The Professional NM1090 PRO PCIe 5.0 SSD delivers speeds up to 14,000MB/s read and 13,000MB/s write1 to provide superior performance for professional-grade systems. Its 6nm controller optimizes heat control for more efficient performance and customers can pair it with an AMD Ryzen or Intel i9 processor for a next-level game experience. The drive features DRAM Cache and SLC dynamic cache to greatly enhance data transfer speeds to reduce wait times and improve system responsiveness. The NQ780 M.2 2280 PCIe 4.0 NVMe SSD is designed with premium technologies to deliver read/write speeds up to 7000/6000MB/s1 and to prevent system lags for both games and work applications. A single-sided design and Intelligent Power Control make it perfect for laptops. Plus, the drive comes with the Lexar DiskMaster SSD management tool so users can perform firmware updates and monitor drive health. "If you're a casual gamer looking for an upgrade, or a creative professional who needs serious speeds to power through projects, Lexar SSDs are able to deliver the performance to improve any system," said Joey Lopez, Director of Marketing. "We're excited to see our range of PCIe storage solutions optimize the systems of students, gamers, professionals, and everyone in between." The NQ780 M.2 2290 PCIe Gen 4.4 NVMe SSD is available in 1TB for an MSRP of $79.99, 2TB for an MSRP of $149.99, and 4TB for an MSRP of $289.99. The Professional NM1090 PRO PCIe 5.0 is available in 1TB for $179.99, 2TB for an MSRP of $269.99, and 4TB coming this summer. Availability Lexar NQ780 M.2 PCIe Gen 4.4 Amazon Lexar Professional NM1090 PRO PCIe 5.0 SSD Amazon Media Elements Lexar® NQ780 PCIe 4.0 NVMe SSD Lexar Professional NM1090 PRO PCIe 5.0 SSD About Lexar For more than 25 years, Lexar has been trusted as a leading global brand of memory solutions. Our award-winning lineup includes memory cards, USB Flash Drives, card readers, solid-state drives, and DRAM. With so many options, it's easy to find the right Lexar solution to fit your needs. Disclosures 1 Up to 7000MB/s read transfer, up to 6000MB/s write. Speeds based on internal testing. Actual performance may vary. Instagram: (Twitter): Lexar. 1737 N First Street, Suite 680, San Jose, CA USA Media Contact Noel LoNoello@ View original content to download multimedia: SOURCE Lexar International
